ClinicalTrials.gg
TerminatedNCT06771921Updated Jan 30, 2026

A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors

A Phase 1/2 interventional study of GEN1078 in Malignant Solid Tumor, sponsored by Genmab. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The sponsor has made the decision to terminate further development of GEN1078 based on emerging safety observations and overall benefit-risk assessment of 1078

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this trial is to measure the following in participants with solid cancers who receive GEN1078.

  • The side effects seen with GEN1078
  • What the body does with GEN1078 once it is administered
  • What GEN1078 does to the body once it is administered
  • How well GEN1078 works against advanced solid tumors

Trial details include:

  • The estimated trial duration is 8 months for an individual participant (the trial duration may vary for each participant).
  • The treatment duration will be an estimated 3-month treatment period (the duration of treatment may vary for each participant).
  • The visit frequency will be daily or visits every few days for the first few months.

All participants will receive active drug; no one will be given placebo.

02

Conditions studied

  • Malignant Solid Tumor
03

In context

Lead sponsor

Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have at least 1 per v1.1 assessed by the investigator.
  • Must have an performance status (ECOG PS) score of 0 to 1.

Dose Escalation Only

  • Participant must have or cytologically confirmed solid tumor(s) for which there is no further available standard therapy likely to confer clinical benefit (or participant is not a candidate or has previously refused such earlier available therapy), and for whom, in the opinion of the investigator, experimental therapy with GEN1078 may be beneficial.
  • Must have either recurrence after, or progression on available relevant standard of care (SoC) anticancer therapies; or are deemed intolerant to or ineligible for, standard curative therapy in the recurrent setting.

Expansion Only

  • Participant must have advanced (unresectable) or , histologically confirmed diagnosis of selected solid cancers.

Key Exclusion Criteria:

  • Has significant cardiovascular impairment within 6 months prior to the first dose of trial drug, including presence of unstable angina, myocardial infarction, congestive heart failure ( [NYHA] class III and IV), or cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy.
  • Known unstable central nervous system (CNS) metastases or any active or history of carcinomatous meningitis.
  • Has been exposed to any of the following prior therapies within the specified timeframes:

    • Prior therapy with a compound targeting the same targets as GEN1078 or any cell-based therapies.
    • Radiotherapy within 14 days prior to C1D1. Palliative radiotherapy of bone metastases up to 7 days prior to C1D1 will be allowed.
    • Treatment with any or non-investigational anticancer agent (including investigational vaccines) or used an invasive investigational medical device within 28 days or 5 half-lives of the drug, whichever is shorter, prior to the first dose of GEN1078.
    • Chemotherapy within 2 weeks prior to the first dose of GEN1078.
    • Prophylaxis with live, attenuated vaccines within 28 days prior to first dose of GEN1078; or prophylaxis with the first and/or subsequent injection(s) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid vaccine within 14 days prior to first dose of GEN1078.
    • Chronic systemic treatment, including , ie, prednisone \>10 milligrams (mg) daily (or equivalent) or a cumulative dose \>140 mg prednisone within 14 days (or equivalent) before the first dose of GEN1078. Replacement therapy (eg, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is permitted.
    • Has received granulocyte colony-stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support within 2 weeks prior to the first dose GEN1078 or being chronically transfusion dependent.
    • Has received other T-cell activating surface marker. Note: Prior treatment with anti-T-cell Ig and ITIM domain (aTIGIT), anti-programmed cell death protein 1 (aPD1), anti-programmed death-ligand 1 (aPDL1), anti-lymphocyte activation gene 3 protein (aLAG3), anti-cytotoxic T-lymphocyte-associated protein 4 (aCTLA-4) is allowed.
    • The initiation of growth factors and bisphosphonates is not allowed during the first 4 weeks of GEN1078 administration, unless agreed upon by the investigator and sponsor medical monitor. However, the use of receptor activator of nuclear factor kappa-Β ligand (RANK-L) inhibitors and bisphosphonates (if on stable dose for at least 4 weeks) is permitted while participating in this trial.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Dose-Escalation

    GEN1078 will be administered as monotherapy until one of the treatment discontinuation criteria has been met.

    Drug: GEN1078

  • Experimental
    Dose Expansion

    GEN1078 will be administered as monotherapy until one of the treatment discontinuation criteria has been met.

    Drug: GEN1078

Interventions

  • DrugGEN1078

    Specified dose on specified days.

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs)

    Toxicities will be graded for severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0, except for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) which will be evaluated according to the American Society for Transplantation and Cellular Therapy (ASTCT) criteria.

    Time frame: Up to 21 days

  2. Dose Escalation: Number of Participants With Adverse Events (AEs)

    Time frame: From first dose until the end of the safety follow-up period (30 days after the last dose)

  3. Dose Expansion: Confirmed Objective Response Rate (ORR)

    Confirmed ORR is defined as the percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by the investigator.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Dose-Escalation and Expansion: Clearance (CL) of GEN1078

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 months)

  2. Dose-Escalation and Expansion: Volume of Distribution (Vd) of GEN1078

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 months)

  3. Dose-Escalation and Expansion: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-last) of GEN1078

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 months)

  4. Dose-Escalation and Expansion: Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC0-∞) of GEN1078

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 months)

  5. Dose-Escalation and Expansion: Maximum Observed Plasma Concentration (Cmax) of GEN1078

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 months)

  6. Dose-Escalation and Expansion: Time to Reach Cmax (Tmax) for GEN1078

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 months)

  7. Dose-Escalation and Expansion: Predose Concentration for GEN1078

    Time frame: Predose up to end of treatment (approximately 3 months)

  8. Dose-Escalation and Expansion: Terminal Half-life (t½) of GEN1078

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 months)

  9. Dose-Escalation and Expansion: Number of Participants with Anti-drug Antibodies (ADAs)

    Time frame: Up to approximately 5 years

  10. Dose Escalation: Confirmed ORR

    Confirmed ORR is defined as the percentage of participants with confirmed BOR of CR or PR based on RECIST v1.1 as assessed by the investigator.

    Time frame: Up to approximately 5 years

  11. Dose-Escalation and Expansion: Duration of Response (DOR)

    DOR is defined as the time from first documentation of response (CR or PR) to the date of the first documented progression or death whichever occurs earlier based on RECIST v1.1 as assessed by the investigator.

    Time frame: Up to approximately 5 years

  12. Dose-Escalation and Expansion: Disease Control Rate (DCR)

    The DCR is defined as the percentage of participants with confirmed BOR of CR, PR, or Stable Disease (SD) according to RECIST v1.1 as assessed by investigator.

    Time frame: Up to approximately 5 years

  13. Dose-Escalation and Expansion: Time to Response (TTR)

    TTR based on investigator assessment is defined as the time from Cycle 1, Day 1 (C1D1) to first documentation of objective response (CR or PR) in participants achieving PR or CR according to RECIST v1.1 as assessed by investigator.

    Time frame: Up to approximately 5 years

  14. Dose Expansion: Number of Participants With AEs

    Time frame: From first dose until the end of the safety follow-up period (30 or 60 days after the last dose)

07

Study locations

6 sites
  • Righshospitalet (Copenhagen University Hospital)
    Copenhagen, Denmark
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Centro Integral Oncologico Clara Campal
    Madrid, Spain
  • Hospital Universitary Fundacion Jimenez Diaz
    Madrid, Spain
  • NEXT Oncology Madrid
    Madrid, Spain
  • Clinica Universidad de Navarra
    Pamplona, Spain
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Jun 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 13, 2025
StartActual
Jan 29, 2025
Primary completionActual
Jun 11, 2025
CompletionActual
Jun 11, 2025
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06771921
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Jan 29, 2025
Primary completion
Jun 11, 2025
Completion
Jun 11, 2025
Last update
Jan 30, 2026

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion